Related Experiment Videos
Cytokine gene therapy in oncology
1Dipartimento di Scienze Biomediche ed Oncologia Umana, Sezione Clinica, University of Torino.
Abstract:
Over the last few years the possibility of introducing foreign material into the genome of host cells has become technically feasible. This has opened a new era in the treatment of congenital disorders, but has also offered potential innovative avenues in the management of cancer patients. Here, we shall discuss how cytokine genes may be successfully transduced into the DNA of different experimental tumours and how through this approach the tumorigenicity of the neoplastic cells may be abrogated. Emphasis will be given on the demonstration that following cytokine gene transfer, namely with the interleukin 2 (IL-2) gene, two of the primary goals of an optimal immunotherapeutic approach, i.e. anti-tumour specificity and memory, may be achieved. Attention will be focused, in particular, on the results so far obtained, as well as on ongoing studies, with human tumour cells engineered to release different cytokine genes. The design and activation of the first clinical protocols aimed at treating advanced cancer patients with cytokine gene-transduced neoplastic cells will also be discussed, together with other strategies of genetic engineering currently under investigation.
Insights
Gene transfer of cytokines, like interleukin-2 (IL-2), into tumor cells shows promise for cancer immunotherapy. This approach aims to create specific anti-tumor responses and lasting immunity in patients.
Area of Science:
- Biotechnology
- Cancer Research
- Immunotherapy
Background:
- Genetic engineering techniques now allow for the introduction of foreign material into host cell genomes.
- This technological advancement presents new possibilities for treating genetic disorders and managing cancer.
- Cytokine gene transfer into tumor cells is being explored as a novel cancer treatment strategy.
Purpose of the Study:
- To discuss the successful transduction of cytokine genes into experimental tumors.
- To demonstrate the abrogation of tumor cell tumorigenicity through gene transfer.
- To highlight the achievement of anti-tumor specificity and memory via cytokine gene therapy, specifically with interleukin-2 (IL-2).
Main Methods:
- Engineering human tumor cells to release various cytokine genes.
- Transducing cytokine genes, such as interleukin-2 (IL-2), into the DNA of experimental tumors.
- Developing and initiating clinical protocols for advanced cancer patients using genetically modified tumor cells.
Main Results:
- Successful transduction of cytokine genes into experimental tumor models.
- Demonstrated abrogation of tumor cell tumorigenicity following gene transfer.
- Evidence of achieving anti-tumor specificity and immunological memory after IL-2 gene transfer.
Conclusions:
- Cytokine gene transfer into tumor cells is a viable strategy for cancer immunotherapy.
- This approach can induce specific anti-tumor immunity and long-term memory.
- Clinical trials are underway to evaluate the efficacy of genetically engineered tumor cells in advanced cancer patients.